We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

3 ‘no-brainer’ FTSE 100 shares I’d buy for 2023

FTSE 100 top picks! Our writer considers diversification, resilience and business quality to find the best shares for his ISA in 2023.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

I’ve kicked off 2023 by looking at which shares I’d like to add to my Stocks and Shares ISA. Today, I’m focused on large-cap FTSE 100 shares.

I’ve always admired fashion retailer Next (LSE:NXT). I reckon it’s the best managed clothing retailer in the UK. I’ve been expecting most retailers to report weak sales, given the cost-of-living crisis.

Should you buy AstraZeneca Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

In contrast, Next lifted its profit outlook on Thursday and reported strong sales over Christmas. It looks like cold weather prompted many to buy coats and other winter items.

Quality business

Higher costs last year put pressure on many retailers’ profit margins. So it was good to see Next talking of lower shipping and raw material costs.

That said, it remained cautious in its outlook for the coming year. That’s no surprise as rising mortgage costs and other inflationary pressures could put further dent household finances.

Overall though, Next is a high-quality business. Its return on capital employed and profit margins are in double digits. It also offers a 3% dividend yield.

I’d consider it a good long-term holding and I’d certainly buy it if I had spare funds.

FTSE 100 bargain

The next FTSE 100 share that I’d buy is discount retailer B&M European Value Retail (LSE:BME). Like Next, it also reported strong Christmas trading yesterday. In the 13 weeks leading up to Christmas, sales rose by 12% compared to the prior year.

It reported “very good performance across all B&M UK categories, both in grocery and general merchandise”. That sounds reassuring to me.

I reckon this stock will prove resilient this year, especially if households tighten their belts.

Another feature I like about this business is that it’s still growing. With a price-to-earnings ratio of 12, it’s also reasonably priced.

To top it off, it has a dividend yield of 4%. That’s around the average for the FTSE 100. But I’d note that this could rise to a juicy 8% yield when factoring in special dividends.

There’s always the risk of competition taking a chunk out of its business though. Many UK retailers could offer similar products at similar prices.

But overall, it looks good to me right now. If I had some extra cash, I’d buy these shares today.

The best medicine

Another defensive FTSE 100 share that I’d buy right now is pharmaceutical giant Astrazeneca (LSE:AZN). It earned £3bn from Covid vaccine sales in 2021. But that’s not why I’m keen on this stock.

Cancer treatment is its main area of focus and is likely to fuel earnings growth over the coming years.

Astrazeneca’s focus on research and development (R&D) is paying dividends. It has been allocating an industry-leading 23% of its sales to its R&D budget.

That’s resulting in ample regulatory approvals and a strong pipeline of new drugs.

With a market capitalisation of over £180bn, it’s now the most valuable company in the FTSE 100. After a strong run up in its share price, is the upside limited?

It’s certainly a risk. It’s also not the cheapest stock among the Footsie giants. That said, I’m a long-term investor. And this business has years of potential growth ahead, in my opinion. As soon as I have some spare cash in my ISA, buying this share will be a ‘no-brainer’ decision for me.

Harshil Patel has no position in any of the shares mentioned. The Motley Fool UK has recommended B&M European Value. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female couple boarding their plane at the airport to go on holiday.
Investing Articles

Can the Rolls-Royce share price reach £15.97 by the end of August?

The Rolls-Royce share price has had a solid run in the last year. Muhammad Cheema takes a look at whether…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Up 1,200% in 5 years, here’s why Nvidia could still be a brilliant value stock

An exciting new announcement that could reshape the PC industry has just pushed Nvidia stock... well, just about nowhere really.

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

How investing £4.50 a day could set you on the way to a £1,505 monthly second income

How can UK stocks with high dividend yields help investors earn a meaningful second income from the price of a…

Read more »

Investing Articles

Up 103% with a P/E of 261 — is this FTSE 100 stock still worth buying?

One FTSE 100 stock is quietly moving higher while most investors are still looking elsewhere — is the market missing…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

The smart money thinks AI stocks look risky — but is there still a chance to buy?

According to fund managers, the AI trade is getting crowded. But they still seem to think it’s the place to…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Barclays shares are 11% below their 52-week high. Could they be a bit of a bargain to consider?

Overpriced or one of the FTSE 100’s hidden gems? James Beard takes a closer look at how the market is…

Read more »

Stack of one pound coins falling over
Investing Articles

Down 65% but yielding 6.7% – is this beaten-down UK stock now a generational bargain?

Harvey Jones says this UK stock is one of the worst FTSE 100 performers but there are sound reasons to…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Is this FTSE stock really 46% undervalued?

Analysts reckon this FTSE stock should be worth nearly 50% more. James Beard considers why there’s so much positivity surrounding…

Read more »